Impact of T-Cell Engagers on COVID-19–Related Mortality in B-Cell Lymphoma Patients Receiving B-Cell Depleting Therapy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose B-cell depleting therapies, including T-cell engager (TCE), are increasingly used for patients with hematologic malignancies, including during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to evaluate the relationship between TCE therapy and COVID-19–related outcomes among patients with COVID-19 and B-cell lymphomas receiving B-cell depleting therapy.Materials and Methods This retrospective cohort study included patients with B-cell lymphoma, who were admitted to Seoul Natio-nal University Hospital with COVID-19 between September 2021 and February 2023, and received B-cell depleting therapy before COVID-19 diagnosis. Multivariable logistic regression was used to identify factors associated with severe to critical COVID-19 and COVID-19–related mortality.Results Of 54 patients with B-cell lymphomas and COVID-19 who received B-cell depleting therapy, 14 were treated with TCE (TCE group) and 40 with rituximab (RTX group). COVID-19–related mortality was higher in the TCE group than in the RTX group (57.1% vs. 12.5%, p=0.002). In multivariable analyses, TCE therapy (adjusted odds ratio [aOR], 7.08; 95% confidence interval [CI], 1.29 to 38.76; p=0.024) and older age (aOR, 1.06; 95% CI, 1.00 to 1.13; p=0.035) were associated with severe to critical COVID-19. TCE therapy (aOR, 8.98; 95% CI, 1.48 to 54.40; p=0.017), older age (aOR, 1.13; 95% CI, 1.02 to 1.26; p=0.022), and prior bendamustine therapy (aOR, 7.78; 95% CI, 1.17 to 51.65; p=0.034) were independent risk factors for COVID-19–related mortality.Conclusion B-cell lymphoma patients treated with TCE had significantly worse outcomes from COVID-19 than those treated with RTX. TCE therapy should be used with caution in B-cell lymphoma patients during the COVID-19 epidemic.
Abstract
Purpose B-cell depleting therapies, including T-cell engager (TCE), are increasingly used for patients with hematologic malignancies, including during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to evaluate the relationship between TCE therapy and COVID-19–related outcomes among patients with COVID-19 and B-cell lymphomas receiving B-cell depleting therapy.Materials and Methods This retrospective cohort study included patients with B-cell lymphoma, who were admitted to Seoul Natio-nal University Hospital with COVID-19 between September 2021 and February 2023, and received B-cell depleting therapy before COVID-19 diagnosis. Multivariable logistic regression was used to identify factors associated with severe to critical COVID-19 and COVID-19–related mortality.Results Of 54 patients with B-cell lymphomas and COVID-19 who received B-cell depleting therapy, 14 were treated with TCE (TCE group) and 40 with rituximab (RTX group). COVID-19–related mortality was higher in the TCE group than in the RTX group (57.1% vs. 12.5%, p=0.002). In multivariable analyses, TCE therapy (adjusted odds ratio [aOR], 7.08; 95% confidence interval [CI], 1.29 to 38.76; p=0.024) and older age (aOR, 1.06; 95% CI, 1.00 to 1.13; p=0.035) were associated with severe to critical COVID-19. TCE therapy (aOR, 8.98; 95% CI, 1.48 to 54.40; p=0.017), older age (aOR, 1.13; 95% CI, 1.02 to 1.26; p=0.022), and prior bendamustine therapy (aOR, 7.78; 95% CI, 1.17 to 51.65; p=0.034) were independent risk factors for COVID-19–related mortality.Conclusion B-cell lymphoma patients treated with TCE had significantly worse outcomes from COVID-19 than those treated with RTX. TCE therapy should be used with caution in B-cell lymphoma patients during the COVID-19 epidemic.
참고문헌 (31)
- Wang Q, "Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19infection", JAMA Oncol, 7, pp.220~227 (2021)
- Passamonti F, "Clinical characteristics and risk factors associ ated with COVID-19 severity in patients with haematological malignancies in Italy : a retrospective, multicentre, cohort study", Lancet Haematol, 7, pp.e737~e745 (2020)
- Yasuda H, "Persistent COVID-19 pneumonia and fail ure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma", Clin Lympho ma Myeloma Leuk, 20, pp.774~776 (2020)
- Yasuda H, "Resolution of one-year persisting COVID-19 pneu monia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab main tenance therapy : a follow-up report and literature review of cases with prolonged infections", Clin Lymphoma Myeloma Leuk, 21, pp.e810~e816 (2021)
- Dulery R, "Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lym phoma treated with B-cell depleting immunotherapy", Am J Hematol, 96, pp.934~944 (2021)
- Salles G, "Rituximab in B-cell hematologic malignancies : a review of 20 years of clinical experience", Adv Ther, 34, pp.2232~2273 (2017)
- Tian Z, "Bispecific T cell engagers : an emerging therapy for management of hematologic malignan cies", J Hematol Oncol, 14, pp.75~ (2021)
- Gonzalez Barca E, "Role of bispecific antibodies in relapsed", refractory diffuse large B-cell lymphoma in the CART era, 2022, pp.13, 909008~
- "Coronavirus disease 2019 (COVID-19) treatment guidelines" (2022)[URL]
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Cheson BD, "Recommendations for initial evaluation, stag ing, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Nyberg T, "Comparative analysis of the risks of hos pitalisation and death associated with SARS-CoV-2 omicron(B. 1. 1. 529)and delta(B. 1. 617. 2)variants in England : a cohort study", Lancet, 399, pp.1303~1312 (2022)
- Perez P, "Specif ic targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody", Nature, 316, pp.354~356 (1985)
- Schuster SJ, "Bispecific antibodies for the treatment of lympho mas : promises and challenges", Hematol Oncol, 39(Suppl 1), pp.113~116 (2021)
- Falchi L, "Bispecific antibodies for the treatment of B-cell lymphoma : promises, unknowns, and opportunities", Blood, 141, pp.467~480 (2023)
- Dickinson MJ, "Glofitamab for relapsed or refractory diffuse large B-cell lymphoma", N Engl J Med, 387, pp.222031~ (2022)
- Budde LE, "Safety and efficacy of mosunetuzumab, a bispe cific antibody, in patients with relapsed or refractory follicular lymphoma : a single-arm, multicentre, phase 2 study", Lancet Oncol, 23, pp.1055~1065 (2022)
- Hutchings M, "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1", 2 study, 2021, pp.398, 1157~1169
- Budde LE, "Single-agent mosunetuzumab shows durable com plete responses in patients with relapsed or refractory B-cell lymphomas : phase I dose-escalation study", J Clin Oncol, 40, pp.481~491 (2022)
- Hutchings M, "Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial", J Clin Oncol, 39, pp.1959~1970 (2021)
- Bannerji R, "Odronextamab, a human CD20xCD3 bispe cific antibody in patients with CD20-positive B-cell malig nancies(ELM-1) : results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial", Lancet Haematol, 9, pp.e327~e339 (2022)
- Thieblemont C, "Epcoritamab, a novel, subcutane ous CD3xCD20 bispecific T-cell-engaging antibody, in relap sed or refractory large B-cell lymphoma : dose expansion in a phase I", II trial, 2023, pp.41, 2238~2247
- Casulo C, "Incidence of hypogam maglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections", Clin Lymphoma Myeloma Leuk, 13, pp.106~111 (2013)
- Aksoy S, "Infectious complications of rituximab in patients with lymphoma dur ing maintenance therapy : a systematic review and meta-anal ysis", Leuk Lymphoma, 50, pp.357~365 (2009)
- Garcia-Suarez J, "Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality : lessons from a large population-based registry study", J Hema tol Oncol, 13, pp.133~ (2020)
- O’Leary AL, "Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron(B. 1. 1. 529)variant predomi nance", Am J Infect Control, 51, pp.603~606 (2023)
- Assanto GM, "Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19 : a retrospective study", Hematol Oncol, 41, pp.34353~ (2023)
- Hagihara M, "Successful elimination of SARS-CoV-2 following vaccination with BNT162b2 after prolonged viral infection in an immuno compromised lymphoma patient", Intern Med, 61, pp.2215~2219 (2022)
- Nakamura S, "Characteristics and outcomes of corona virus disease 2019(COVID-19)patients with cancer : a single center retrospective observational study in Tokyo, Japan", Int J Clin Oncol, 26, pp.485~493 (2021)
- Fung M, "Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine", Clin Infect Dis, 68, pp.247~255 (2019)
- Anolik JH, "B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny", Clin Immunol, 122, pp.139~145 (2007)